Log in

OTCMKTS:SIGASIGA Technologies Stock Price, Forecast & News

+1.16 (+17.79 %)
(As of 08/7/2020 04:00 PM ET)
Today's Range
Now: $7.68
50-Day Range
MA: $6.29
52-Week Range
Now: $7.68
Volume1.06 million shs
Average Volume276,744 shs
Market Capitalization$622.44 million
P/E RatioN/A
Dividend YieldN/A
SIGA Technologies, Inc., a commercial-stage pharmaceutical company, focuses on the health security and infectious disease markets in the United States. Its lead product is TPOXX, an orally administered antiviral drug for the treatment of human smallpox disease caused by variola virus. The company was founded in 1995 and is headquartered in New York, New York.
Read More
SIGA Technologies logo

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.48 out of 5 stars

Industry, Sector and Symbol

Industry Biotechnology
Current SymbolOTCMKTS:SIGA
Previous SymbolNASDAQ:SIGA



Sales & Book Value

Annual SalesN/A



Market Cap$622.44 million
Next Earnings Date11/3/2020 (Estimated)
+1.16 (+17.79 %)
(As of 08/7/2020 04:00 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive SIGA News and Ratings via Email

Sign-up to receive the latest news and ratings for SIGA and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

SIGA Technologies (OTCMKTS:SIGA) Frequently Asked Questions

How has SIGA Technologies' stock been impacted by COVID-19 (Coronavirus)?

SIGA Technologies' stock was trading at $4.75 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, SIGA stock has increased by 61.7% and is now trading at $7.68.
View which stocks have been most impacted by Coronavirus

When is SIGA Technologies' next earnings date?

SIGA Technologies is scheduled to release its next quarterly earnings announcement on Tuesday, November 3rd 2020.
View our earnings forecast for SIGA Technologies

Has SIGA Technologies been receiving favorable news coverage?

News articles about SIGA stock have been trending very positive this week, according to InfoTrie. InfoTrie identifies positive and negative media coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. SIGA Technologies earned a media sentiment score of 4.0 on InfoTrie's scale. They also gave press coverage about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the company's share price in the next several days.
View the latest news about SIGA Technologies

Who are some of SIGA Technologies' key competitors?

What other stocks do shareholders of SIGA Technologies own?

Based on aggregate information from My MarketBeat watchlists, some companies that other SIGA Technologies investors own include Anavex Life Sciences (AVXL), Celsion (CLSN), Catalyst Pharmaceuticals (CPRX), Cytokinetics (CYTK), Novavax (NVAX), Protalix Biotherapeutics (PLX), SCYNEXIS (SCYX), Catalyst Biosciences (CBIO), Coherus Biosciences (CHRS) and Fate Therapeutics (FATE).

Who are SIGA Technologies' key executives?

SIGA Technologies' management team includes the following people:
  • Dr. Phillip Louis Gomez III, CEO & Director (Age 53, Pay $1.59M)
  • Mr. Daniel J. Luckshire, Exec. VP, CFO & Sec. (Age 49, Pay $1.24M)
  • Dr. Dennis E. Hruby, VP & Chief Scientific Officer (Age 68, Pay $1.43M)
  • Ms. Robin E. Abrams, Gen. Counsel & Chief Admin. Officer (Age 56, Pay $1.07M)

What is SIGA Technologies' stock symbol?

SIGA Technologies trades on the OTCMKTS under the ticker symbol "SIGA."

Who are SIGA Technologies' major shareholders?

SIGA Technologies' stock is owned by a variety of institutional and retail investors. Top institutional investors include AltraVue Capital LLC (2.71%), Legato Capital Management LLC (0.68%), Bessemer Group Inc. (0.22%), DAVENPORT & Co LLC (0.21%), Assenagon Asset Management S.A. (0.20%) and Northeast Financial Consultants Inc (0.16%). Company insiders that own SIGA Technologies stock include Daniel J Luckshire, Dennis E Hruby, James Antal, Paul G Savas and Phillip Louis Gomez III.
View institutional ownership trends for SIGA Technologies

Which institutional investors are selling SIGA Technologies stock?

SIGA stock was sold by a variety of institutional investors in the last quarter, including AltraVue Capital LLC, Legato Capital Management LLC, and UBS Group AG.
View insider buying and selling activity for SIGA Technologies

Which institutional investors are buying SIGA Technologies stock?

SIGA stock was acquired by a variety of institutional investors in the last quarter, including Assenagon Asset Management S.A., Bessemer Group Inc., Northeast Financial Consultants Inc, Nisa Investment Advisors LLC, WINTON GROUP Ltd, Swiss National Bank, SG Americas Securities LLC, and Cresset Asset Management LLC. Company insiders that have bought SIGA Technologies stock in the last two years include Daniel J Luckshire, Paul G Savas, and Phillip Louis Gomez III.
View insider buying and selling activity for SIGA Technologies

How do I buy shares of SIGA Technologies?

Shares of SIGA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is SIGA Technologies' stock price today?

One share of SIGA stock can currently be purchased for approximately $7.68.

How big of a company is SIGA Technologies?

SIGA Technologies has a market capitalization of $622.44 million. SIGA Technologies employs 41 workers across the globe.

What is SIGA Technologies' official website?

The official website for SIGA Technologies is www.siga.com.

How can I contact SIGA Technologies?

SIGA Technologies' mailing address is 27 EAST 62ND STREET, NEW YORK NY, 10065. The biotechnology company can be reached via phone at 212-672-9100 or via email at [email protected]

This page was last updated on 8/8/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.